Volasertib trihydrochloride

Volasertib (BI 6727) trihydrochloride is a dihydropteridinone derivative that potently and selectively inhibits Polo-like kinase 1 (PLK1), PLK2, and PLK3, acting as an orally active ATP-competitive inhibitor with an IC50 of 0.87 nM against PLK1, 5 nM against PLK2, and 56 nM against PLK3. Its mechanism includes inducing mitotic arrest and apoptosis, with significant antitumor activity observed in various cancer models.

Cl.Cl.Cl.CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O|wU:28.29,5.1,wD:25.22,(16.69,,;,-12.23,;4.18,-12.23,;-12.27,2.97,;-10.94,3.74,;-9.6,2.97,;-8.27,3.74,;-8.27,5.28,;-9.6,6.05,;-6.94,6.05,;-6.94,2.97,;-5.6,3.74,;-4.27,2.97,;-2.93,3.74,;-1.6,2.97,;-1.6,1.43,;-.27,.66,;1.07,1.43,;1.07,2.97,;-.27,3.74,;-.27,5.28,;1.07,6.05,;2.4,.66,;3.73,1.43,;2.4,-.88,;3.73,-1.65,;3.73,-3.19,;5.07,-3.96,;6.4,-3.19,;6.4,-1.65,;5.07,-.88,;7.74,-3.96,;9.07,-3.19,;10.4,-3.96,;10.4,-5.5,;11.74,-6.27,;11.74,-7.81,;12.51,-9.15,;10.97,-9.15,;9.07,-6.27,;7.74,-5.5,;-4.27,1.43,;-5.6,.66,;-6.94,1.43,;-8.27,.66,;-8.27,-.88,;-9.6,1.43,;-10.94,.66,)|